Saturday, October 3, 2026

USD/CNH Bearish By 4% In The Last 21 Sessions

ViaNews Editorial Team

February 19, 2023

USD/CNH Bearish By 4% In The Last 21 Sessions

(VIANEWS) - USD/CNH (USDCNH) has been up by 4.22% for the last 21 sessions. At 14:11 EST on Sunday, 19 February, USD/CNH (USDCNH) is $6.87.

USD/CNH's yearly highs and lows, it's 0.006% up from its 52-week low and 0% down from its 52-week high.

News about

  • Eur/usd slides in asia to test 1.0650 as US dollar bulls flex. According to FXStreet on Friday, 17 February, "At the time of writing, EUR/USD is trading at 1.06552 and has made a low of 1.0649 so far, sliding from 1.0675."
  • Eur/usd set to head lower but holding above parity – danske bank. According to FXStreet on Friday, 17 February, "We have long argued the strategic case for a lower EUR/USD based on relative terms of trade, real rates (growth prospects) and relative unit labour costs. ", "As a difference to the period from September to early January, Eurozone equities are now underperforming peers, which could be an indication that EUR/USD has peaked."
  • Eur/usd bears keep the reins at six-week low as ECB appears less hawkish than fed. According to FXStreet on Friday, 17 February, "The first daily closing below the 50-day Exponential Moving Average (EMA), around 1.06860 by the press time, since early November 2022 directs EUR/USD toward a 10-week-old ascending support line, close to 1.0620 at the latest.", "On a different page, the fresh US-China tension and Russia's refrain from stepping back when it comes to attacking Ukraine also weigh on the risk appetite and the EUR/USD prices, due to the US Dollar's safe-haven demand."
  • Eur/usd: overshoot to support at 1.0460 cannot be excluded as a risk – scotiabank. According to FXStreet on Friday, 17 February, "A third consecutive lower weekly close and losses, if rather limited so far, below key short-term support at 1.0660 target more declines ahead for EUR/USD from a technical point of view."

More news about USD/CNH (USDCNH).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com